Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 19.13% is 57% below its 4-year average of 44.42%, near the low end of its 4-year range (11.61%–96.85%).
As of the fiscal period ended Wednesday, December 31, 2025. 24.46% above its 12-month average of 15.37%.
Annual fiscal-year return on invested capital; no daily interpolation. Historical series through 2025-12-31.
RETURN ON INVESTED CAPITAL (ROIC)
19.13%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
15.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
31.31%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.46%
CURRENT VS 3Y AVG
-38.90%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.87%
median of 701 covered companies
CURRENT VS SECTOR MEDIAN
+156.48%
vs the sector median at left
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$215.94M
Return on Invested Capital (ROIC)
19.13%
TTM Avg
15.37%
3Y Avg
31.31%
5Y Avg
N/A
Market Cap
$214.35M
Return on Invested Capital (ROIC)
-43.74%
TTM Avg
-105.81%
3Y Avg
-81.36%
5Y Avg
-65.49%
Market Cap
$214.16M
Return on Invested Capital (ROIC)
26.14%
TTM Avg
3.79%
3Y Avg
-12.27%
5Y Avg
-17.37%
Market Cap
$214.44M
Return on Invested Capital (ROIC)
-70.80%
TTM Avg
-76.09%
3Y Avg
-51.87%
5Y Avg
-42.00%
Market Cap
$217.61M
Return on Invested Capital (ROIC)
-71.04%
TTM Avg
-53.65%
3Y Avg
-40.34%
5Y Avg
-35.55%
Market Cap
$214.24M
Return on Invested Capital (ROIC)
8.84%
TTM Avg
15.21%
3Y Avg
-9.34%
5Y Avg
-32.56%
Market Cap
$207.87M
Return on Invested Capital (ROIC)
-33.10%
TTM Avg
-20.50%
3Y Avg
-16.94%
5Y Avg
-23.40%
Market Cap
$223.55M
Return on Invested Capital (ROIC)
-36.49%
TTM Avg
-7.39%
3Y Avg
-25.88%
5Y Avg
-24.07%
Market Cap
$207.34M
Return on Invested Capital (ROIC)
14.99%
TTM Avg
15.04%
3Y Avg
13.17%
5Y Avg
12.12%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $215.94M | 19.13% | 15.37% | 31.31% | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | -43.74% | -105.81% | -81.36% | -65.49% |
| Compugen Ltd. (CGEN)vs › | $214.16M | 26.14% | 3.79% | -12.27% | -17.37% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.44M | -70.80% | -76.09% | -51.87% | -42.00% |
| Alector, Inc. (ALEC)vs › | $217.61M | -71.04% | -53.65% | -40.34% | -35.55% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 8.84% | 15.21% | -9.34% | -32.56% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.87M | -33.10% | -20.50% | -16.94% | -23.40% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.55M | -36.49% | -7.39% | -25.88% | -24.07% |
| Pro-Dex, Inc. (PDEX)vs › | $207.34M | 14.99% | 15.04% | 13.17% | 12.12% |
| Electra Therapeutics Inc. (ETRA)vs › | $202.90M | N/A | N/A | N/A | N/A |
ROIC
19.1%
ROE
21.2%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 19.13% |
| 2024-12-31 | 11.61% |
| 2023-12-31 | 13.23% |
| 2022-12-31 | 81.26% |
| 2021-12-31 | 96.85% |
